Track IDEAYA Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

IDEAYA Biosciences, Inc. IDYA · Stock Open IDEAYA Biosciences, Inc. in new tab

31.83 USD
EPS
-4.50
P/B
2.82
ROE
-38.46
Beta
0.08
Target Price
50.69 USD
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
EPS-4.50
Book Value11.30
Price to Book2.82
Debt/Equity2.72
% Insiders2.500%
Growth
Revenue Growth-0.95%
Estimates
Forward P/E-7.67
Forward EPS-4.15
Target Mean Price50.69

DCF valuation

Model fair value for IDEAYA Biosciences, Inc. (IDYA)
Result
Sign in to run the valuation for IDYA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Strong buy · mean target 50.69 USD (low 30.00, high 66.00) · as of 16 Nov 2026
Low 30.00
Mean 50.69
High 66.00
Price 31.83
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

IDEAYA Biosciences, Inc. Logo IDEAYA Biosciences, Inc. Analysis (IDYA)

United States Health Care Official Website Stock

Is IDEAYA Biosciences, Inc. a good investment? IDEAYA Biosciences, Inc. (IDYA) is currently trading at 31.83 USD. Market analysts have a consensus price target of 50.69 USD. This suggests a potential upside from current levels.

Earnings Schedule: IDEAYA Biosciences, Inc. is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is -4.15.

Investor FAQ

Does IDEAYA Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is IDEAYA Biosciences, Inc.?

IDEAYA Biosciences, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of -4.50.

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) IDYA
FRA (Germany) 30J.F
STU (Germany) 30J.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion